Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have earned an average rating of “Moderate Buy” from the eleven analysts that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $44.25.

Several research analysts have recently commented on STOK shares. Weiss Ratings reissued a “sell (d)” rating on shares of Stoke Therapeutics in a report on Friday, August 7th. Wedbush lifted their price objective on Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. JPMorgan Chase & Co. assumed coverage on Stoke Therapeutics in a research report on Friday, August 21st. They issued an “overweight” rating and a $40.00 price objective for the company. Canaccord Genuity Group reduced their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. Finally, The Goldman Sachs Group restated a “buy” rating on shares of Stoke Therapeutics in a report on Thursday, September 10th.

Insiders Place Their Bets

In other news, Director Edward M. Md Kaye sold 12,567 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total transaction of $402,521.01. Following the transaction, the director directly owned 124,557 shares in the company, valued at approximately $3,989,560.71. This represents a 9.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 5,545 shares of the stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $30.67, for a total transaction of $170,065.15. Following the sale, the insider directly owned 20,110 shares in the company, valued at $616,773.70. This trade represents a 21.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 32,916 shares of company stock valued at $1,025,302 in the last 90 days. 9.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Versant Capital Management Inc grew its holdings in shares of Stoke Therapeutics by 22.6% in the 2nd quarter. Versant Capital Management Inc now owns 1,951 shares of the company’s stock valued at $64,000 after buying an additional 359 shares during the period. First Trust Advisors LP increased its position in shares of Stoke Therapeutics by 0.5% in the 1st quarter. First Trust Advisors LP now owns 163,459 shares of the company’s stock valued at $5,322,000 after buying an additional 780 shares in the last quarter. Harbour Investments Inc. raised its stake in Stoke Therapeutics by 312.9% during the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after buying an additional 898 shares during the period. Quantbot Technologies LP acquired a new stake in Stoke Therapeutics during the 2nd quarter worth $34,000. Finally, KBC Group NV bought a new position in Stoke Therapeutics during the first quarter worth about $36,000.

Stoke Therapeutics Stock Performance

STOK opened at $25.88 on Wednesday. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -7.75 and a beta of 1.23. The firm’s 50-day simple moving average is $30.12 and its 200-day simple moving average is $31.34. Stoke Therapeutics has a twelve month low of $20.32 and a twelve month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.13). The firm had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. As a group, sell-side analysts anticipate that Stoke Therapeutics will post -3.52 EPS for the current fiscal year.

About Stoke Therapeutics

Stoke Therapeutics, Inc is a biotechnology company focused on developing RNA-based medicines for severe genetic diseases. The company’s approach is designed to increase the production of functional proteins by selectively targeting RNA splicing, a process that helps determine how genetic information is translated into proteins.

Stoke’s technology is based on its TANGO platform, which uses antisense oligonucleotides to promote the inclusion of productive genetic sequences in messenger RNA.